{"entity":{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","aka":["DESTINY-Lung05"],"tldr":"A phase 2 trial of Trastuzumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC is a phase 2 interventional study registered as NCT05246514 by AstraZeneca, with 72 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2024-11-04. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: HER2-mutant Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05246514","url":"https://clinicaltrials.gov/study/NCT05246514"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","her2-mutant-nsclc"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05246514-clin-lung-cancer-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05246514","phase":"2","setting":"An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)","sponsor":"AstraZeneca","started":"2022-07-13","startedType":"actual","yearReported":2024,"enrolled":72,"enrolledBasis":"registry","outcomes":[{"endpoint":"ICR-assessed ORR (Objective Response Rate)","primary":true,"unit":"%","arms":[{"name":"T-DXd Arm","n":72,"value":56.9,"note":"95% CI 44.7 to 68.6; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT05246514?tab=results"},{"endpoint":"OS (Overall Survival)","unit":"months","arms":[{"name":"T-DXd Arm","n":72,"value":21,"note":"95% CI 17.5 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT05246514?tab=results"},{"endpoint":"ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)","unit":"months","arms":[{"name":"T-DXd Arm","n":72,"value":15.5,"note":"95% CI 9.9 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-12-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT05246514?tab=results"}]},"route":"/trials/nct05246514/","neighbours":{"cancer":[{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/"}]}}